Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (26564)	2/10/2000 12:30:00 PM
From: Bidder	Respond to of 150070

HCCAE! Bouncing back nicely!!!

To: SSP who wrote (26564)	2/10/2000 12:32:00 PM
From: Katie Kommando	Respond to of 150070

WASP . . . I bought some today at .81 cents. New PR firm is on board: Thursday February 10, 9:17 am Eastern Time Company Press Release Wasatch Pharmaceutical Retains OTC Financial Network for Comprehensive Investor Awareness Campaign MIDVALE, Utah--(BW HealthWire)--Feb. 10, 2000--Wasatch Pharmaceutical, Inc. (OTC BB: WASP), a leader in the research, development and distribution of dermatological treatments for skin disorders including acne and psoriasis, today announced that it has retained OTC Financial Network, a division of National Financial Communications Corp., to direct its comprehensive shareholder and investor relations campaign. ``After a decade and a half of research, Wasatch has developed a line of products and treatments for a wide variety of skin disorders that constitute a breakthrough in the field of dermatology' stated OTC Financial Network President Geoffrey Eiten. ``The imminent release of these products and treatments on the open marketplace, combined with the Company's plan to establish a chain of treatment clinics nationwide, will drive its dramatic growth over the next 36 months.' The Company reported that it anticipates total net income to exceed $35 million by fiscal year 2005, the target date for completion of its chain of 350 treatment centers. Wasatch Chief Executive Officer, Gary V. Heesch, stated, ``As we prepare for a period of intense and profitable growth, we are excited to join forces with the professionals at OTC Financial. Their proven expertise in communicating crucial information to the investment community will prove of tremendous assistance to Wasatch as we build our reputation in the pharmaceutical arena.' Wasatch Pharmaceutical, Inc. is a leading research and development entity in the field of dermatology. The Company targets its products and treatments to a wide variety of specific dermatological disease areas, including cystic acne, psoriasis, eczema, and seborrhea. OTC Financial Network, a division of National Financial Communications Corp. of Needham, Massachusetts, is a full-service financial communications and investor relations firm specializing in the representation of small-cap companies. Forward-looking statements in this release are made pursuant to the ``safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products introduced by competitors, changes in the rates of subscriber acquisition and retention, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Contact: National Financial Network Robert Weiss, 781/444-6100 ext.11 or Wasatch Pharmaceutical, Inc. Gary V. Heesch, 801/566-9688